Immuno Japan Inc.

Chugai Seiyaku Kabushiki Kaisha

Institute of Immunology Co., Ltd.

Biomedics Inc.

Tetsuo Nakamura

Shunji Mishiro

Hiroaki Okamoto

Masayuki Tsuchiya

Hiroyuki Aburatani

Eduardo Agustin Padlan

Masanori Numazaki

Sadakazu Usuda

Atsuhiko Machida

Yoshiyuki Nishikawa

Tatsuro Shimaoka

Kunio Ando

Tomoyoshi Hosokawa

Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.

Cell growth inhibitors containing anti-glypican 3 antibody

A murine anti-CD20 monoclonal antibody having cell growth inhibitory activities is disclosed. Cell growth inhibitory activities include apoptosis against human CD20 antigen expressing cells in culture of the CD20 antigen expressing cells without effector cells. The anti-CD20 monoclonal antibody is incorporated into chimeric anti-CD20 monoclonal antibodies in which the amino acid sequences of the variable regions of the anti-CD20 monoclonal antibody and the amino acid sequences of the constant regions of human immunoglobulin are fused. Also a humanized anti-CD20 monoclonal antibody is described which includes all of the variable region CDRs of the H chain of the anti-CD20 monoclonal antibody and all of the variable region CDRs of the L chain of the anti-CD20 monoclonal antibody and an amino acid sequence of human immunoglobulin. A nucleotide sequence encoding the amino acid sequence of the chimeric or humanized anti-CD20 monoclonal antibody can be expressed in mammalian cells.

Anti-CD20 monoclonal antibody

Novel nucleic acids, proteins, peptides, antigens, and antibodies related to non-A, non-B hepatitis, and non-A, non-B hepatitis diagnostic reagents using those materials.

Non-A non-B hepatitis related nucleic acids proteins peptides antigens

Use of oligosaccharides for the treatment of pruritus cutaneus

The noncoding region, containing at least 324 nucleotides, of the 5' terminus of non-A, non-B hepatitis virus is disclosed. Also disclosed is the nucleotide sequence of the structural gene which is upstream of the noncoding region. Oligonucleotide primers derived from these regions can be used to to detect non-A, non-B hepatitis virus.

Oligonucleotide primers, and their application for high-fidelity

Non-A, non-B hepatitis related nucleic acids, proteins, peptides,

Non-A, non-B hepatitis (NANB hepatitis) virus RNA and its corresponding polypeptide, related antigen, antibody, and detection systems for detecting NANB hepatitis antigen or antibodies.

Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides,

Hepatitis C virus oligonucleotides and a system to determine hepatitis C virus genotypes with polymerase chain reaction utilizing those oligonucleotides as primers.

Oligonucleotides and determination system of HCV genotypes

Non-A, Non-B Hepatitis Virus Genome RNA is disclosed along with cDNA and Virus Antigen Protein.

Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein

A composition containing ascorbic acid and/or its derivatives and aspirin and/or its derivatives is an effective analgesic and anti-inflammatory medicine. A method for reducing the side effects of aspirin in a mammal involves the administration of an effective amount of a pharmaceutical composition comprising ascorbic acid and/or its derivatives and aspirin/or its derivatives.

Analgesic and anti-inflammatory medicine

Non-A, Non-B hepatitis virus genome RNA is disclosed along with cDNA and virus antigen protein.

A polypetide vaccine is disclosed with the amino acid sequence of Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-Gly-Gly-Ser-Ser-Ser-Gly-Thr-Va l that bears the receptor for polymerized human serum albumin capable of raising antibodies to inhibit the access and entry of hepatitis B virus (HBV) to hepatocytes. The polypeptide vaccine is also shown in which the 9th amino acid residue (Phe) is replaced by leucine. In addition, there is disclosed hepatitis B polypeptide vaccine P31 which is capable of raising antibodies to block the attachment of HBV to hepatocytes.

Growing community of inventors

Tokyo, Japan

Tetsuo Nakamura